Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 19 studies | 62% ± 14% | |
| lung | 18 studies | 36% ± 11% | |
| intestine | 12 studies | 25% ± 8% | |
| kidney | 9 studies | 36% ± 17% | |
| brain | 8 studies | 31% ± 11% | |
| liver | 6 studies | 31% ± 11% | |
| pancreas | 5 studies | 39% ± 17% | |
| bone marrow | 5 studies | 41% ± 24% | |
| uterus | 5 studies | 31% ± 15% | |
| lymph node | 5 studies | 55% ± 18% | |
| breast | 4 studies | 28% ± 9% | |
| eye | 3 studies | 26% ± 7% | |
| adrenal gland | 3 studies | 35% ± 16% | |
| placenta | 3 studies | 23% ± 6% | |
| prostate | 3 studies | 27% ± 7% | |
| thymus | 3 studies | 42% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 10808.32 | 1445 / 1445 | 100% | 139.29 | 183 / 183 |
| intestine | 100% | 13596.12 | 966 / 966 | 100% | 171.52 | 527 / 527 |
| ovary | 100% | 9672.72 | 180 / 180 | 100% | 158.58 | 430 / 430 |
| prostate | 100% | 11909.83 | 245 / 245 | 100% | 186.49 | 502 / 502 |
| stomach | 100% | 10432.83 | 359 / 359 | 100% | 160.92 | 286 / 286 |
| brain | 100% | 10430.82 | 2641 / 2642 | 100% | 238.01 | 705 / 705 |
| lung | 100% | 16124.26 | 578 / 578 | 100% | 185.80 | 1154 / 1155 |
| bladder | 100% | 12815.81 | 21 / 21 | 100% | 162.21 | 503 / 504 |
| kidney | 100% | 17486.69 | 89 / 89 | 100% | 195.32 | 899 / 901 |
| thymus | 100% | 13942.16 | 653 / 653 | 100% | 193.61 | 603 / 605 |
| breast | 100% | 14472.27 | 459 / 459 | 100% | 209.27 | 1114 / 1118 |
| uterus | 100% | 11622.06 | 170 / 170 | 100% | 152.73 | 457 / 459 |
| liver | 100% | 6458.31 | 226 / 226 | 100% | 105.15 | 404 / 406 |
| skin | 100% | 11510.97 | 1809 / 1809 | 99% | 142.13 | 469 / 472 |
| adrenal gland | 100% | 12161.82 | 258 / 258 | 97% | 118.71 | 223 / 230 |
| pancreas | 97% | 5572.67 | 318 / 328 | 100% | 162.56 | 178 / 178 |
| adipose | 100% | 14162.91 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 15577.33 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 186.59 | 29 / 29 |
| peripheral blood | 100% | 21724.28 | 929 / 929 | 0% | 0 | 0 / 0 |
| spleen | 100% | 16904.63 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 170.82 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 51.73 | 1 / 1 |
| muscle | 99% | 7545.06 | 798 / 803 | 0% | 0 | 0 / 0 |
| heart | 98% | 8564.26 | 841 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 98% | 98.20 | 78 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0034063 | Biological process | stress granule assembly |
| GO_0031648 | Biological process | protein destabilization |
| GO_1905636 | Biological process | positive regulation of RNA polymerase II regulatory region sequence-specific DNA binding |
| GO_0016607 | Cellular component | nuclear speck |
| GO_0032991 | Cellular component | protein-containing complex |
| GO_0016604 | Cellular component | nuclear body |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0010494 | Cellular component | cytoplasmic stress granule |
| GO_0005634 | Cellular component | nucleus |
| GO_0140297 | Molecular function | DNA-binding transcription factor binding |
| GO_0031435 | Molecular function | mitogen-activated protein kinase kinase kinase binding |
| GO_0031625 | Molecular function | ubiquitin protein ligase binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0050699 | Molecular function | WW domain binding |
| GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
| GO_0120283 | Molecular function | protein serine/threonine kinase binding |
| GO_0002039 | Molecular function | p53 binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0030971 | Molecular function | receptor tyrosine kinase binding |
| Gene name | DAZAP2 |
| Protein name | DAZ-associated protein 2 (Deleted in azoospermia-associated protein 2) (Proline-rich transcript in brain protein) |
| Synonyms | KIAA0058 PRTB |
| Description | FUNCTION: In unstressed cells, promotes SIAH1-mediated polyubiquitination and degradation of the serine/threonine-protein kinase HIPK2, probably by acting as a loading factor that potentiates complex formation between HIPK2 and ubiquitin ligase SIAH1 . In response to DNA damage, localizes to the nucleus following phosphorylation by HIPK2 and modulates the expression of a subset of TP53/p53 target genes by binding to TP53 at target gene promoters . This limits the expression of a number of cell death-mediating TP53 target genes, reducing DNA damage-induced cell death . Enhances the binding of transcription factor TCF7L2/TCF4, a Wnt signaling pathway effector, to the promoters of target genes (By similarity). Plays a role in stress granule formation . . |
| Accessions | F8VUW5 ENST00000551313.1 E9PE89 ENST00000412716.8 [Q15038-1] ENST00000436900.2 ENST00000449723.7 [Q15038-6] ENST00000549555.5 [Q15038-5] Q15038 S4R3Q0 ENST00000425012.6 [Q15038-2] ENST00000604900.5 ENST00000549732.6 [Q15038-3] ENST00000439799.6 [Q15038-4] |